Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.36 |
| ▸ | LIPC | P11150 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23466734 | 0.90 | LIPG (0.40) | LIPCLIPGCYP3A4 | |
| SCHEMBL6134978 | 0.86 | LIPG (0.43) | LSSLIPCLIPGCES2EPHX2 | |
| SCHEMBL6135635 | 0.82 | MLNR (0.36) | LIPCLIPGCES2 | |
| SCHEMBL6135131 | 0.82 | LIPC (0.34) | LSSLIPCLIPG | |
| SCHEMBL6135437 | 0.82 | CES2 (0.35) | ALDH1A1CYP3A4CES2TSHR | |
| SCHEMBL6134246 | 0.79 | POLB (0.32) | LIPG | |
| SCHEMBL2912964 | 0.77 | KCNQ3 (0.32) | ALDH1A1KDM4E | |
| SCHEMBL27658735 | 0.77 | LIPC (0.36) | LIPCLIPG | |
| SCHEMBL21221365 | 0.76 | LIPG (0.39) | LIPCLIPGSMN1; SMN2KDM4EHPGD | |
| SCHEMBL6132348 | 0.75 | HPGD (0.46) | ALDH1A1SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | LSS 251/4885LIPC 4424/4885LIPG 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.